In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles

British Journal of Clinical Pharmacology

Volumn 80, Issue 5, 2015, Pages 1122-1130

  Hertz, Daniel L ^a   Snavely, Anna C ^b   McLeod, Howard L ^c   Walko, Christine M ^c   Ibrahim, Joseph G ^d   Anderson, Steven ^e   Weck, Karen E ^d   Magrinat, Gustav ^f   Olajide, Oludamilola ^g   Moore, Susan ^g   Raab, Rachel ^h   Carrizosa, Daniel R ⁱ   Corso, Steven ^j   Schwartz, Garry ^k   Peppercorn, Jeffrey M ^l   Evans, James P ^d   Jones, David R ^m   Desta, Zeruesenay ^m   Flockhart, David A ^m   Carey, Lisa A ^d   Irvin, William J ^d,n   more..

^a UNIVERSITY OF MICHIGAN   (United States)

^b RTI INTERNATIONAL   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e LABORATORY CORPORATION OF AMERICA   (United States)

^f Moses Cone Sports Medicine Center   (United States)

^g Rex Hematology/Oncology Associates   (United States)

^h EAST CAROLINA UNIVERSITY   (United States)

ⁱ LEVINE CANCER INSTITUTE   (United States)

^j PA   (United States)

^k Levine Cancer Institute   (United States)

^l DUKE CANCER INSTITUTE   (United States)

^m INDIANA UNIVERSITY   (United States)

ⁿ Bon Secours Cancer Institute   (United States)

more..

Author keywords

activity score; CYP2D6; endoxifen; N desmethyl tamoxifen; pharmacogenetic; tamoxifen

Indexed keywords

CYTOCHROME P450 2D6; ENDOXIFEN; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; ALLELE; ARTICLE; COHORT ANALYSIS; CONCENTRATION AT STEADY-STATE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; ENZYME METABOLISM; GENOTYPE; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; METABOLIC RATIO; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME; BLOOD; CLINICAL TRIAL; FEMALE; GENETIC ASSOCIATION STUDY; GENETICS; METABOLISM; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTINEOPLASTIC AGENTS, HORMONAL; CYTOCHROME P-450 CYP2D6; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; MIDDLE AGED; PHENOTYPE; TAMOXIFEN; YOUNG ADULT;

EID: 84946494342     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12665     Document Type: Article

References (32)

1. Bernard S, Neville KA, Nguyen AT, Flockhart DA,. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: Clinical implications. Oncologist 2006; 11: 126-35.
2. Gaedigk A,. Complexities of CYP2D6 gene analysis and interpretation. Int Rev Psychiatry 2013; 25: 534-53.
3. Ingelman-Sundberg M, Daly AK, Nebert DW,. Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Database 2008; 2010.
4. Meijerman I, Sanderson LM, Smits PH, Beijnen JH, Schellens JH,. Pharmacogenetic screening of the gene deletion and duplications of CYP2D6. Drug Metab Rev 2007; 39: 45-60.
5. Crews KR, Gaedigk A, Dunnenberger HM, Klein TE, Shen DD, Callaghan JT, Kharasch ED, Skaar TC, Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther 2012; 91: 321-6.
6. Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, Skaar TC, Muller DJ, Gaedigk A, Stingl JC,. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther 2013; 93: 402-8.
7. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS,. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 2008; 83: 234-42.
8. Borges S, Desta Z, Jin Y, Faouzi A, Robarge JD, Philip S, Nguyen A, Stearns V, Hayes D, Rae JM, Skaar TC, Flockhart DA, Li L,. Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol 2010; 50: 450-8.
9. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. The Lancet 1998; 351: 1451-67.
10. Early Breast Cancer Trialists' Collaborative Group. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378: 771-84.
11. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA,. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003; 95: 1758-64.
12. Desta Z, Ward BA, Soukhova NV, Flockhart DA,. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 2004; 310: 1062-75.
13. Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW, Nikoloff DM, Hillman G, Fontecha MR, Lawrence HJ, Parker BA, Wu AHB, Pierce JP,. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther 2011; 89: 718-25.
14. Saladores P, Murdter T, Eccles D, Chowbay B, Zgheib NK, Winter S, Ganchev B, Eccles B, Gerty S, Tfayli A, Lim JSL, Yap YS, Ng RCH, Wong NS, Dent R, Habbal MZ, Schaeffeler E, Eichelbaum M, Schroth W, Schwab M, Brauch H,. Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer. Pharmacogenomics J 2015; 15: 84-94.
15. Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell'orto P, Biasi MO, Thurlimann B, Lyng MB, Ditzel HJ, Neven P, Debled M, Maibach R, Price KN, Gelber RD, Coates AS, Goldhirsch A, Rae JM, Viale G,. Breast International Group (BIG) 1-98 Collaborative Group. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst 2012; 104: 441-51.
16. Leyland-Jones B, Regan MM, Bouzyk M, Kammler R, Tang W, Pagani O, Maibach R, Dell'Orto P, Thurlimann B, Price KN, Viale G,. Outcome According to CYP2D6 Genotype among Postmenopausal Women with Endocrine-Responsive Early Invasive Breast Cancer Randomized inthe BIG 1-98 Trial. SABCS 2010; General Session 1.
17. Goetz MP, Suman VJ, Hoskin TL, Gnant M, Filipits M, Safgren SL, Kuffel M, Jakesz R, Rudas M, Greil R, Dietze O, Lang A, Offner F, Reynolds CA, Weinshilboum RM, Ames MM, Ingle JN,. CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clin Cancer Res 2013; 19: 500-7.
18. Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon W, Suman VJ, Ames MM, Safgren SL, Kuffel MJ, Ulmer HU, Bolander J, Strick R, Beckmann MW, Koelbl H, Weinshilboum RM, Ingle JN, Eichelbaum M, Schwab M, Brauch H,. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009; 302: 1429-36.
19. Hertz DL, McLeod HL, Irvin WJ,. Tamoxifen and CYP2D6: A contradiction of data. Oncologist 2012; 17: 620-30.
20. Province MA, Goetz MP, Brauch H, Flockhart DA, Hebert JM, Whaley R, Suman VJ, Schroth W, Winter S, Zembutsu H, Mushiroda T, Newman WG, Lee MM, Ambrosone CB, Beckmann MW, Choi J, Dieudonne A, Fasching PA, Ferraldeschi R, Gong L, Haschke-Becher E, Howell A, Jordan LB, Hamann U, Kiyotani K, Krippl P, Lambrechts D, Latif A, Langsenlehner U, Lorizio W, Neven P, Nguyen AT, Park B, Purdie CA, Quinlan P, Renner W, Schmidt M, Schwab M, Shin J, Stingl JC, Wegman P, Wingren S, Wu AHB, Ziv E, Zirpoli G, Thompson AM, Jordan VC, Nakamura Y, Altman RB, Ames MM, Weinshilboum RM, Eichelbaum M, Ingle JN, Klein TE,. CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 2013; doi: 10.1038/clpt.2013.186. [Epub ahead of print].
21. Kiyotani K, Mushiroda T, Zembutsu H, Nakamura Y,. Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies. J Hum Genet 2013; 58: 327-33.
22. Irvin WJ, Walko CM, Weck KE, Ibrahim JG, Chiu WK, Dees EC, Moore SG, Olajide OA, Graham ML, Canale ST, Raab RE, Corso SW, Peppercorn JM, Anderson SM, Friedman KJ, Ogburn ET, Desta Z, Flockhart DA, McLeod HL, Evans JP, Carey LA,. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with rReduced CYP2D6 metabolism: a multicenter study. J Clin Oncol 2011; 29: 3232-9.
23. Hicks JK, Swen JJ, Gaedigk A,. Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization. Curr Drug Metab 2014; 15: 218-32.
24. Relling MV, Klein TE,. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther 2011; 89: 464-7.
25. Murdter TE, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G, Simon W, Fasching PA, Fehm T, Eichelbaum M, Schwab M, Brauch H,. Activity levels of Tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther 2011; 89: 708-17.
26. Muroi Y, Takahashi M, Saito T, Sakuyama K, Niinuma Y, Ito M, Tsukada C, Ohta K, Endo Y, Oda A, Hirasawa N, Hiratsuka M,. Functional characterization of wild-type and 49 CYP2D6 allelic variants for N-desmethyltamoxifen 4-hydroxylation activity. Drug Metab Pharmacokinet 2014; 29: 360-6.
27. Abduljalil K, Frank D, Gaedigk A, Klaassen T, Tomalik-Scharte D, Jetter A, Jaehde U, Kirchheiner J, Fuhr U,. Assessment of activity levels for CYP2D61, CYP2D62, and CYP2D641 genes by population pharmacokinetics of dextromethorphan. Clin Pharmacol Ther 2010; 88: 643-51.
28. Wang D, Poi MJ, Sun X, Gaedigk A, Leeder JS, Sadee W,. Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity. Hum Mol Genet 2014; 23: 268-78.
29. Gaedigk A, Garcia-Ribera C, Jeong HE, Shin JG, Hernandez-Sanchez JT,. Resolution of a clinical AmpliChip CYP450 Test no call: discovery and characterization of novel CYP2D61 haplotypes. Pharmacogenomics 2014; 15: 1175-84.
30. Wang D, Papp AC, Sun X,. Functional characterization of CYP2D6 enhancer polymorphisms. Hum Mol Genet 2015; 24: 1556-62.
31. Teft WA, Gong IY, Dingle B, Potvin K, Younus J, Vandenberg TA, Brackstone M, Perera FE, Choi YH, Zou G, Legan RM, Tirona RG, Kim RB,. CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy. Breast Cancer Res Treat 2013; 139: 95-105.
32. Klein DJ, Thorn CF, Desta Z, Flockhart DA, Altman RB, Klein TE,. PharmGKB summary: tamoxifen pathway, pharmacokinetics. Pharmacogenet Genomics 2013; 23: 643-7.